文献速递抗栓抗凝管理肝肾功能剂量调整

日本非瓣膜性房颤患者中直接口服抗凝药与华法林的疗效与安全性直接比较:全国队列研究

Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan.
PubMed 文献 · Clin Pharmacol Ther · 2024-05-31

该研究利用日本全国保险理赔数据库,对2015年9月至2018年2月首次接受DOAC或华法林治疗的NVAF患者进行回顾性观察性队列研究,采用倾向评分逆概率加权调整背景因素,并以阴性对照结局考虑肾功能为未测量混杂因素。结果显示DOAC在疗效终点(卒中或系统性栓塞)和安全性终点(临床显著出血)均优于华法林,达比加群的有用性低于艾多沙班和利伐沙班。

要点

  • DOAC在疗效终点(卒中或系统性栓塞)上优于华法林,HR为0.72-0.81。
  • DOAC在安全性终点(临床显著出血)上优于华法林,HR为0.80-0.88。
  • 达比加群在日本NVAF患者中的有用性低于艾多沙班和利伐沙班。

核心结论

  • 在日本NVAF患者中,DOAC在疗效和安全性方面均优于华法林。
  • 艾多沙班和利伐沙班是日本NVAF患者中最有用的抗凝药。
  • 达比加群的有用性低于艾多沙班和利伐沙班。

研究设计与样本

  • 回顾性观察性队列研究,使用日本全国保险理赔数据库。
  • 纳入2015年9月至2018年2月首次接受DOAC或华法林治疗的NVAF患者。
  • 采用倾向评分逆概率加权调整背景因素,并以阴性对照结局考虑肾功能为未测量混杂因素。

主要发现

  • DOAC组疗效终点(卒中或系统性栓塞)的风险比华法林组低,HR为0.72-0.81。
  • DOAC组安全性终点(临床显著出血)的风险比华法林组低,HR为0.80-0.88。
  • 净临床获益显示DOAC优于华法林,HR为0.75-0.82。

临床怎么用

  • 在日本NVAF患者中,可优先考虑使用艾多沙班或利伐沙班而非华法林或达比加群。
  • 临床选择抗凝药时需结合患者肾功能等个体因素综合评估。

局限性

  • 研究为回顾性观察性设计,可能存在未测量混杂因素。
  • 仅以阴性对照结局考虑肾功能为未测量混杂因素,但未完全排除其影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulant drugs (DOACs) are available in addition to warfarin for the treatment of patients with non-valvular atrial fibrillation (NVAF). Anticoagulants are useful for practical pharmacotherapy in Asian populations, but their responses are different from those in Caucasian populations. Therefore, we aimed to identify the most useful anticoagulant using a nationwide insurance claims database in Japan. We extracted information on patients with NVAF treated with DOACs or warfarin for the first time between September 2015 and February 2018 to conduct a retrospective observational cohort study using the claims database of Japan. We calculated hazard ratios (HR) of effectiveness and safety endpoints among DOACs or warfarin after adjusting for backgrounds by propensity scores (inverse probability weighting). Using negative control outcomes, we considered renal function as an unmeasured confounding factor. After adjusting for their backgrounds, patients treated with DOACs showed higher effectiveness endpoints (stroke or systemic embolism) than those treated with warfarin (HR; 0.72-0.81) and higher safety in terms of safety end points (clinically significant bleeding) (HR; 0.80-0.88). The net clinical benefit, which reflects the actual clinical usefulness, indicates the advantages of DOACs over warfarin (HR; 0.75-0.82). Dabigatran had lower usefulness than edoxaban and rivaroxaban in Japanese patients treated with NVAF, even after considering the unmeasured confounding factor of kidney function. Based on practical clinical data, edoxaban and rivaroxaban were the most useful anticoagulants in Japanese patients with NVAF.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Katayama S, Aoki Y, Akita A, et al. Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan. Clin Pharmacol Ther. 2024. PMID: 38818726. doi:10.1002/cpt.3331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。